Conference icon

Conference

Substrate reduction therapy.

Abstract:

UNLABELLED: The therapeutic options for lysosomal storage diseases (LSDs) have expanded greatly over the past decade, although for many disorders there is still no effective treatment. Given that the majority of LSDs involve pathological changes in both the brain and peripheral tissues, effective treatment of central nervous system (CNS) and peripheral manifestations still remains a considerable technical challenge. Type 1 Gaucher disease has two approved treatment modalities - enzyme replac...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Pharmacology
Role:
Author
Volume:
97
Issue:
457
Pages:
88-93
Publication date:
2008-04-05
DOI:
EISSN:
1651-2227
ISSN:
0803-5326
URN:
uuid:ca8b3d7b-dfc3-4975-86dc-82864e010331
Source identifiers:
185124
Local pid:
pubs:185124

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP